Advertisement


Alexander Lesokhin, MD: Can Patients With Relapsed/Refractory Multiple Myeloma Successfully Pause or Discontinue Elranatamab?

ASH 2025

Advertisement

Alexander Lesokhin, MD, of Memorial Sloan Kettering Cancer Center, discusses results of a retrospective analysis from the phase II MagnetisMM-3 trial. A post hoc analysis was conducted of the subgroup of patients enrolled in the study who had a prolonged treatment interruption or who permanently discontinued elranatamab and maintained their responses for 6 months or longer (Abstract 2269). 

 



Related Videos

Leukemia

Amir Fathi, MD, on Newly Diagnosed AML: Azacitidine and Venetoclax vs Conventional Induction Chemotherapy

Amir Fathi, MD, of Massachusetts General Hospital, discusses data from the phase II PARADIGM trial, which prospectively tested whether azacitidine plus venetoclax was superior to intensive induction chemotherapy in fit patients with newly diagnosed acute myeloid leukemia (AML)and could challenge the current treatment standard (Abstract 6). 

Leukemia

Anand Patel, MD, on Ph-Positive ALL: TKI Plus Inotuzumab Ozogamicin–Based Therapy

Anand Patel, MD, of the University of Chicago, discusses results from a phase II trial that showed tyrosine kinase inhibitor plus inotuzumab ozogamicinbased therapy resulted in major molecular response in patients newly diagnosed with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) (Abstract 441). 

Leukemia

Othman Al-Sawaf, MD, PhD, on Previously Untreated CLL: Fixed-Duration vs Continuous Targeted Treatment

Othman Al-Sawaf, MD, PhD, of the University Hospital of Cologne, presents results from the phase III CLL17 trial, which compared continuous ibrutinib monotherapy to fixed-duration venetoclax plus obinutuzumab to fixed-duration venetoclax plus ibrutinib for previously untreated patients with chronic lymphocytic leukemia (CLL) (Abstract 1). 

Myelodysplastic Syndromes

Amer Zeidan, MBBS, on Lower-Risk MDS: Treatment-Emergent Cytopenias and Clinical Response

Amer Zeidan, MBBS, of Yale School of Medicine, discusses findings from an analysis of the IMerge trial, which explored the possible association between imetelstat-related cytopenias and hemoglobin increasea measure linked to red blood cell transfusion independence achievement—in patients with lower-risk myelodysplastic syndromes (MDS) (Abstract 490). 

Multiple Myeloma

Jack Khouri, MD, on Multiple Myeloma: Burixafor and Propranolol With G-CSF Before Transplant

Jack Khouri, MD, of Cleveland Clinic, describes the findings of a phase II trial which investigated the safety and efficacy of burixafor (GPC-100), a potent and selective small -molecule antagonist of CXCR4, and propranolol with granulocyte colony-stimulating factor (G-CSF) for the mobilization of hematopoietic progenitor cells (HPC) in patients with multiple myeloma. Researchers aimed to boost the bone marrow HPC niche and optimize mobilization in patients with multiple myeloma eligible for autologous hematopoietic cell transplant (Abstract 1050). 

Advertisement

Advertisement




Advertisement